Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Mayne Pharma Group ( (AU:MYX) ) just unveiled an announcement.
Mayne Pharma Group Limited has reported a 5% increase in unaudited group revenues to approximately $300 million for the first nine months of the 2025 financial year, driven by significant growth in Women’s Health. However, the company faced challenges in the Dermatology segment due to market declines and competition. The company has entered a new licensing agreement with Sol-Gel Technologies to acquire US rights to TWYNEO® and EPSOLAY®, enhancing its dermatology portfolio. This strategic move is expected to drive growth and align with Mayne Pharma’s strategy to improve market access for innovative products. The company anticipates a strong financial performance in FY25, with expected underlying EBITDA growth of 105-123% over FY24, and plans to focus on sales execution and marketing efforts across its segments.
More about Mayne Pharma Group
Mayne Pharma Group Limited is a pharmaceutical company based in Adelaide, Australia, focusing on the development and commercialization of branded and generic pharmaceuticals. The company operates in segments including Women’s Health, Dermatology, and International markets, with a mission to expand access to high-quality medicines.
YTD Price Performance: 50.69%
Average Trading Volume: 2,022
Technical Sentiment Signal: Sell
Current Market Cap: $365.9M
For a thorough assessment of MYX stock, go to TipRanks’ Stock Analysis page.